Circassia Pharmaceuticals plc announced the appointment of Jonathan Emms to the newly-created role of Chief Operating Officer (COO). As COO he will further strengthen Circassia's commercial focus and lead the company's global commercial strategy and operational management. He will also join the company's Board as an Executive Director when he joins Circassia on 2 September 2019. At the same time Circassia's Senior Vice President of R&D, Rod Hafner, will step down from the Board after 11 years as a Director, reflecting the company's commercial focus now the approval process for Duaklir and Tudorza's sNDA are complete. He will remain a key member of Circassia's Senior Management Team and will continue in his role leading the company's business development, supply chain, medical affairs, regulatory and quality activities. Prior to joining the company, Jonathan was Chief Commercial Officer for Pfizer's Internal Medicines organisation, where he led commercial activities across the company's global operations.